According to Zacks, “China Biologic Products, Inc., through its indirect majority-owned subsidiary, is principally engaged in the research, development, production, manufacturing and sale of plasma-based biopharmaceutical products to hospitals and other health care facilities in China. Its subsidiary, Shandong Taibang Biological Products Co. Ltd., operates from its manufacturing facility located in Taian City, Shandong Province. The Company’s principal products include its approved human albumin and immunoglobulin products. These human albumin products are mainly used to increase blood volume and its immunoglobulin products are used for the treatment and prevention of diseases. “
Several other brokerages have also recently issued reports on CBPO. Credit Suisse Group AG raised shares of China Biologic Products from a neutral rating to an outperform rating in a research note on Tuesday, July 5th. Jefferies Group boosted their target price on shares of China Biologic Products from $136.00 to $155.00 and gave the company a buy rating in a report on Friday, August 5th.
China Biologic Products (NASDAQ:CBPO) opened at 118.63 on Tuesday. The company has a 50 day moving average of $119.76 and a 200-day moving average of $117.29. China Biologic Products has a one year low of $94.53 and a one year high of $144.29. The company has a market cap of $3.19 billion, a P/E ratio of 34.21 and a beta of 1.55.
China Biologic Products (NASDAQ:CBPO) last announced its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.16 by $0.10. China Biologic Products had a net margin of 29.66% and a return on equity of 19.65%. The company earned $91.40 million during the quarter, compared to analysts’ expectations of $87.60 million. During the same quarter in the prior year, the company earned $1.06 EPS. China Biologic Products’s revenue was up 15.6% compared to the same quarter last year. On average, equities analysts expect that China Biologic Products will post $4.33 earnings per share for the current fiscal year.
In other China Biologic Products news, insider Zhijing Cbpo Liu sold 1,968 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $124.32, for a total value of $244,661.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Ming Yang sold 21,092 shares of the business’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $124.32, for a total transaction of $2,622,157.44. Following the completion of the transaction, the chief financial officer now owns 24,782 shares in the company, valued at $3,080,898.24. The disclosure for this sale can be found here. 2.68% of the stock is currently owned by company insiders.
Several institutional investors have recently modified their holdings of CBPO. Baillie Gifford & Co. bought a new position in shares of China Biologic Products during the second quarter valued at approximately $155,307,000. Capital Research Global Investors raised its position in shares of China Biologic Products by 42.5% in the second quarter. Capital Research Global Investors now owns 3,031,654 shares of the biopharmaceutical company’s stock valued at $322,325,000 after buying an additional 904,377 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of China Biologic Products by 590.9% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 397,893 shares of the biopharmaceutical company’s stock valued at $42,304,000 after buying an additional 340,304 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of China Biologic Products by 266.3% in the second quarter. Ameriprise Financial Inc. now owns 189,841 shares of the biopharmaceutical company’s stock valued at $20,183,000 after buying an additional 138,020 shares in the last quarter. Finally, AGF Investments Inc. raised its position in shares of China Biologic Products by 116,781.6% in the second quarter. AGF Investments Inc. now owns 133,245 shares of the biopharmaceutical company’s stock valued at $14,164,000 after buying an additional 133,131 shares in the last quarter. Hedge funds and other institutional investors own 71.71% of the company’s stock.
About China Biologic Products
China Biologic Products, Inc (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research, development, manufacturing and sales of human plasma-based biopharmaceutical products in China. It operates in the manufacture and sales of human plasma products segment. It has a product portfolio with over 20 various dosage forms of plasma products and other biopharmaceutical products across over nine categories.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for China Biologic Products Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for China Biologic Products Inc. and related companies with MarketBeat.com's FREE daily email newsletter.